drugset / Trial / NCT02201043

Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis

NCT02201043

Phase 2 Completed 197 enrolled Shanghai Pharmaceuticals Holding Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

1. Evaluate the efficacy and safety of taking thalidomide tablets once daily in the treatment of active ankylosing spondylitis. 2. To explore dose-effect relationships of taking thalidomide tablets once daily in the treatment of active ankylosing spondylitis, as well as selecting the appropriate dose for the further larger scale clinical trials.

Timeline

Start
2013-02
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Thalidomide Other / unclassified 100 mg Oral
Comparator Thalidomide Other / unclassified 150 mg Oral